Menu Search
Equities

Genmab A/S

GMAB:CPH

Genmab A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)2,040.00
  • Today's Change14.00 / 0.69%
  • Shares traded23.76k
  • 1 Year change-27.71%
  • Beta1.2207
Data delayed at least 15 minutes, as of May 17 2024 10:43 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 09-May-24
Select bar for recommendation details.
Recommendations09-May-24
Buy4
Outperform10
Hold8
Underperform1
Sell2

Share price forecast in DKK

The 21 analysts offering 12 month price targets for Genmab A/S have a median target of 2,700.00, with a high estimate of 4,900.00 and a low estimate of 1,600.00. The median estimate represents a 33.27% increase from the last price of 2,026.00.
High141.9%4,900.00
Med33.3%2,700.00
Low-21.0%1,600.00

Earnings history & estimates in DKK

On May 02, 2024, Genmab A/S reported 1st quarter 2024 earnings of 20.18 per share. This result exceeded the 11.83 consensus of the 10 analysts covering the companyand exceeded last year's 1st quarter results by 16.75.
The next earnings announcement is expected on Aug 01, 2024.
Average growth rate+149.07%
Genmab A/S reported annual 2023 earnings of 66.02 per share on Feb 14, 2024.
Average growth rate+34.47%
More ▼

Revenue history & estimates in DKK

Genmab A/S had 1st quarter 2024 revenues of 4.14bn. This bettered the 3.83bn consensus of the 11 analysts covering the company. This was 45.16% above the prior year's 1st quarter results.
Average growth rate+11.82%
Genmab A/S had revenues for the full year 2023 of 16.47bn. This was 12.87% above the prior year's results.
Average growth rate+39.32%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.